1.
|
Miller DC, Hafez KS and Stewart A:
Prostate carcinoma presentation, diagnosis and staging: an update
from the National Cancer Data Base. Cancer. 98:1169–1172. 2003.
View Article : Google Scholar : PubMed/NCBI
|
2.
|
Von Eschenbach AC: The biologic dilemma of
early carcinoma of prostate. Cancer. 78:326–329. 1996.PubMed/NCBI
|
3.
|
Grignon DJ and Hammond EH: College of
American Pathologists Conference XXVI on clinical relevance of
prognostic markers in solid tumors. Report of the Prostate Cancer
Working Group. Arch Pathol Lab Med. 119:1122–1126. 1995.
|
4.
|
Hockenbery D, Nunez C and Milliam C: Bcl-2
is an inner mitochondrial membrane protein that blocks programmed
cell death. Nature. 348:334–338. 1990. View
Article : Google Scholar : PubMed/NCBI
|
5.
|
Levine AJ: p53, the cellular gatekeeper
for growth and division. Cell. 88:323–325. 1997. View Article : Google Scholar : PubMed/NCBI
|
6.
|
Issacs JT: Molecular markers for prostate
cancer metastasis: developing diagnostic methods for predicting the
aggressiveness of prostate cancer. Am J Pathol. 150:1511–1521.
1997.PubMed/NCBI
|
7.
|
Grossfeld CD, Olumi AF and Connolly JA:
Locally recurrent prostate tumours following either radiation
therapy or radical prostatectomy have changes in Ki-67 labelling
index, p53 and bcl-2 immunoreactivity. J Urol. 159:1437–1443. 1998.
View Article : Google Scholar
|
8.
|
Chakravarthi S, Linda TH, Thani PM and
Nadeem IB: Role of apoptosis and abnormalities in expression of
bcl-2 in benign nodular hyperplasia of prostate. Res J of Biol Sci.
4:836–841. 2009.
|
9.
|
Piris MA, Pezzella F and Martinez Montero
JC: p53 and bcl2 expression in high grade B-cell lymphomas. Br J
Cancer. 69:3371994. View Article : Google Scholar : PubMed/NCBI
|
10.
|
Masuda M, Takano Y and Iki M: Prognostic
significance of Ki-67, p53 and bcl-2 expression in prostate cancer
patients with lymph node metastases: a retrospective
immunohistochemical analysis. Pathol Int. 48:41–46. 1998.
View Article : Google Scholar
|
11.
|
Soini Y and Paakko P: Extent of apoptosis
in relation to p53 and bcl-2 expression in germ cell tumors. Hum
Pathol. 27:1221–1226. 1996. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Shurbaji MS, Kalbfeisch JH and Thurmond S:
Immunohistochemical detection of p53 protein as a prognostic
indicator in prostate cancer. Hum Pathol. 26:106–109. 1999.
View Article : Google Scholar : PubMed/NCBI
|
13.
|
Prendergest NJ, Atkins MR and Schatte EC:
p53 immunohistochemical and genetic alterations are associated at
high incidence with post-irradiated locally persistent prostate
carcinoma. J Urol. 155:1685–1692. 1996. View Article : Google Scholar : PubMed/NCBI
|
14.
|
Cheng L, Sebo JT and Pisanlsky T: p53
protein overexpression is associated with increased cell
proliferation in patients with locally recurrent prostate carcinoma
after radiation therapy. Cancer. 85:1293–1299. 1999. View Article : Google Scholar : PubMed/NCBI
|
15.
|
Fox SB, Persad RA and Royds J: p53 and
c-myc expression in stage Al prostatic adenocarcinoma: useful
prognostic determinants? J Urol. 150:490–494. 1993.PubMed/NCBI
|
16.
|
Kallakury BV, Figge J and Ross JS:
Association of p53 immunoreactivity with high Gleason tumor grade
in prostatic adenocarcinoma. Hum Pathol. 25:92–96. 1994. View Article : Google Scholar : PubMed/NCBI
|
17.
|
Bauer JJ, Sesterhenn IA and Mostofi FK:
Elevated levels of apoptosis regulator proteins p53 and bcl-2 are
independent prognostic biomarkers in surgically treated clinically
localized prostate cancer. J Urol. 156:1511–1516. 1996. View Article : Google Scholar
|
18.
|
Matsushima N, Kitamura T and Goto T:
Combined analysis with bcl-2 and p53 immunostaining predicts poorer
prognosis in prostatic carcinoma. J Urol. 158:2278–2283. 1997.
View Article : Google Scholar : PubMed/NCBI
|
19.
|
Bubendorf L, Sauter G and Moch H:
Prognostic significance of bcl-2 in clinically localized prostate
cancer. Am J Pathol. 148:15571996.PubMed/NCBI
|